Viread Approved for Hepatitis B

Already sanctioned to treat HIV

Related Encyclopedia • Acidophilus • Adenocarcinoma of the Lung and Brain Metastases • Antioxidants • Arteriohepatic Dysplasia More... Related Healthscout Videos A Welcome Message from Survivor PJ Hamel Smother Says "Cut!" Maryann and Paula When's the Next Free Mammogram Day? October 17, 2008!!! More... Related Animations • Breast Self-Exam Video • Colon Cancer • Hepatitis More... Related Drug Information • Epogen • Iressa • Klor-Con • Klor-Con ER More... Related News Articles • Radioactive 'Seed' Rx Helps Women With Implants Fight Breast Cancer • Corticosteroids Linked to Pneumonia • Uninsured Likely Organ Donors, But Not Recipients • Transfusing Anemic Cancer Patients Boosts Clot Risk More...

TUESDAY, Aug. 12 (HealthDay News) -- Viread (tenofovir disoproxil fumarate) has been approved by the U.S. Food and Drug Administration to treat chronic hepatitis B infection in adults.

The Gilead Sciences drug has been approved since 2001 to treat HIV/AIDS.

Text Continues Below

---

A serious liver disease, chronic hepatitis B affects about 400 million people globally and some 2 million in the United States, the manufacturer said in a news release. Asian Americans account for nearly half of all cases of the infection, which is a leading cause of liver cancer.

A once-daily tablet, Viread blocks an enzyme called HBV DNA polymerase, which is needed by the hepatitis B virus to replicate in liver cells.

More information

The FDA has more about this drug's approval history.